Evidence map›Paper›PMID 41346458›Full record

ReviewAsia Pacific allergy2025

Chinese expert consensus on intranasal anticholinergics for allergic rhinitis.

Xian Li, Xueyan Wang, Qintai Yang, Jianjun Chen, Hao Tian, Meiping Lu, Tingting Ma, Yana Zhang, Yue Zhou, Jiao Xia and 17 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Asia Pacific allergy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Xian LiDepartment of Allergy, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Xueyan WangDepartment of Allergy, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
Qintai YangDepartment of Otorhinolaryngology-Head and Neck Surgery, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
Jianjun ChenDepartment of Otorhinolaryngology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Hao TianDepartment of Otorhinolaryngology Head and Neck Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Meiping LuDepartment of Otorhinolaryngology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Tingting MaDepartment of Allergy, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
Yana ZhangDepartment of Otorhinolaryngology-Head and Neck Surgery, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
Yue ZhouDepartment of Otorhinolaryngology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Jiao XiaDepartment of Otorhinolaryngology Head and Neck Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Lei ChengDepartment of Otorhinolaryngology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Jian LiDepartment of Otorhinolaryngology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
Huanhai LiuDepartment of Otolaryngology-Head and Neck Surgery, Second Affiliated Hospital of Naval Medical University, Shanghai, China.
Jianfeng LiuDepartment of Otolaryngology-Head and Neck Surgery, China-Japan Friendship Hospital, Beijing, China.
Zheng LiuDepartment of Otolaryngology, Zhongnan Hospital of Wuhan University, Wuhan, China.
Wei LvDepartment of Otolaryngology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Qianhui QiuDepartment of Otolaryngology and Head and Neck Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
Chengshuo WangDepartment of Allergy, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Xiangdong WangDepartment of Allergy, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Yu XuDepartment of Rhinology and Allergy, Otolaryngology-Head and Neck Surgery Centre, Renmin Hospital of Wuhan University, Wuhan, China.
Yuanteng XuDepartment of Otorhinolaryngology & Head Neck Surgery, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Yucheng YangDepartment of Otorhinolaryngology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Jing YeDepartment of Oto rhinolaryngology & Head Neck Surgery, the First Affiliated Hospital of Nanchang University, Nanchang, China.
Hongmeng YuENT Institute and Department of Otolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, China.
Dongdong ZhuDepartment of Otorhinolaryngology Head and Neck Surgery, China-Japan Union Hospital of Jilin University, Changchun, China.
Yuan ZhangDepartment of Allergy, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Luo ZhangDepartment of Allergy, Beijing Tongren Hospital, Capital Medical University, Beijing, China.ORCID https://orcid.org/0000-0002-0910-9884

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Allergic rhinitis (AR) is a prevalent inflammatory condition of the nasal mucosa, characterized by rhinorrhea, nasal congestion, sneezing, and itching. Among these symptoms, rhinorrhea and nasal congestion are the most common complaints of AR patients. By blocking acetylcholine binding with muscarinic (M) receptors, intranasal anticholinergics have been recommended by guidelines as an "add-on" or second-line therapy to control rhinorrhea in patients with AR. Bencycloquidium bromide is a highly selective M1/M3 receptor antagonist that can reduce excessive mucus secretion and suppress type 2 inflammation in AR, while also demonstrating efficacy in alleviating overall nasal symptoms. In this consensus, we systematically review the role of acetylcholine and M receptors in AR pathogenesis, the key findings from clinical trials on intranasal anticholinergics for AR management and the evidence-based recommendations from experts in Allergy and Rhinology, hoping to guide physicians in the standardized and precise use of intranasal anticholinergics for AR patients.

Indexed as

Allergic rhinitisChinaexpert consensusintranasal anticholinergics

Identifiers

PMID41346458
PMCPMC12672180

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.